Evidence map›Paper›PMID 27459960›Full record

ArticleRetrovirology2016

HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB.

Suha Saleh, Hao K Lu, Vanessa Evans, David Harisson, Jingling Zhou, Anthony Jaworowski, Georgina Sallmann, Karey Y Cheong, Talia M Mota, Surekha Tennakoon and 11 more

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Complex Relationships between HIV-1 Integrase and Its Cellular Partners.International journal of molecular sciences · 2022
    Review
  11. Roles of peptidyl prolyl isomerase Pin1 in viral propagation.Frontiers in cell and developmental biology · 2022
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

Suha SalehDoherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.
Hao K LuDoherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.
Vanessa EvansDoherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.
David HarissonCentre for Biomedical Research, Burnet Institute, Melbourne, Australia.
Jingling ZhouCentre for Biomedical Research, Burnet Institute, Melbourne, Australia.
Anthony JaworowskiDepartment of Infectious Diseases, Alfred Health, Monash University, Melbourne, Australia.
Georgina SallmannDoherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.
Karey Y CheongDoherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.
Talia M MotaDoherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.
Surekha TennakoonDoherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.
Thomas A AngelovichCentre for Biomedical Research, Burnet Institute, Melbourne, Australia.
Jenny AndersonDoherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.
Andrew HarmanCentre for Virus Research, Westmead Millennium Institute, University of Sydney, Sydney, Australia.
Anthony CunninghamCentre for Virus Research, Westmead Millennium Institute, University of Sydney, Sydney, Australia.
Lachlan GrayDepartment of Infectious Diseases, Alfred Health, Monash University, Melbourne, Australia.
Melissa ChurchillDepartment of Infectious Diseases, Alfred Health, Monash University, Melbourne, Australia.
Johnson MakDepartment of Infectious Diseases, School of Medicine, Deakin University, Melbourne, Australia.
Heidi DrummerDepartment of Infectious Diseases, Alfred Health, Monash University, Melbourne, Australia.
Dimitrios N VatakisDivision of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Sharon R LewinDoherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia.
Paul U CameronDoherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia. paul.cameron@unimelb.edu.au.ORCID 0000-0002-1906-6945
Burnet Institute · AUThe University of Melbourne · AUThe University of Sydney · AUDeakin University · AUUniversity of California, Los Angeles · US

Funding

Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PALMER, SARAH ELIZABETH · 2011 to 2015
$29.5M
Effects of cocaine on HIV infection of quiescent T cellsR21DA031036 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VATAKIS, DIMITRIOS N · 2011 to 2012
$424k
Impact of HIV infection on anti-tumor CD8 responses in vivoR21AI106472 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VATAKIS, DIMITRIOS N · 2013 to 2014
$412k
The role of chemokines in the establishment of HIV latencyR56AI095073 · NIAID · MONASH UNIVERSITY · PI LEWIN, SHARON RUTH · 2012 to 2012
$271k
NIAID NIH HHS R21 AI106472NIAID NIH HHS R56 AI095073NIAID NIH HHS U19 AI096109NIDA NIH HHS R21 DA031036
6 · The paper itself

Abstract

backgroundEradication of HIV cannot be achieved with combination antiretroviral therapy (cART) because of the persistence of long-lived latently infected resting memory CD4(+) T cells. We previously reported that HIV latency could be established in resting CD4(+) T cells in the presence of the chemokine CCL19. To define how CCL19 facilitated the establishment of latent HIV infection, the role of chemokine receptor signalling was explored.

resultsIn resting CD4(+) T cells, CCL19 induced phosphorylation of RAC-alpha serine/threonine-protein kinase (Akt), nuclear factor kappa B (NF-κB), extracellular-signal-regulated kinase (ERK) and p38. Inhibition of the phosphoinositol-3-kinase (PI3K) and Ras/Raf/Mitogen-activated protein kinase/ERK kinase (MEK)/ERK signalling pathways inhibited HIV integration, without significant reduction in HIV nuclear entry (measured by Alu-LTR and 2-LTR circle qPCR respectively). Inhibiting activation of MEK1/ERK1/2, c-Jun N-terminal kinase (JNK), activating protein-1 (AP-1) and NF-κB, but not p38, also inhibited HIV integration. We also show that HIV integrases interact with Pin1 in CCL19-treated CD4(+) T cells and inhibition of JNK markedly reduced this interaction, suggesting that CCL19 treatment provided sufficient signals to protect HIV integrase from degradation via the proteasome pathway. Infection of CCL19-treated resting CD4(+) T cells with mutant strains of HIV, lacking NF-κB binding sites in the HIV long terminal repeat (LTR) compared to infection with wild type virus, led to a significant reduction in integration by up to 40-fold (range 1-115.4, p = 0.03). This was in contrast to only a modest reduction of 5-fold (range 1.7-11, p > 0.05) in fully activated CD4(+) T cells infected with the same mutants. Finally, we demonstrated significant differences in integration sites following HIV infection of unactivated, CCL19-treated, and fully activated CD4(+) T cells.

conclusionsHIV integration in CCL19-treated resting CD4(+) T cells depends on NF-κB signalling and increases the stability of HIV integrase, which allow subsequent integration and establishment of latency. These findings have implications for strategies needed to prevent the establishment, and potentially reverse, latent infection.

Indexed as

Virus IntegrationVirus LatencyCD4-Positive T-LymphocytesChemokine CCL19Gene Expression Regulation, ViralHIV-1HIV IntegraseHumansNF-kappa BReceptors, CCRSignal TransductionVirus ReplicationCCL19 protein, humanChemokine CCL19HIV IntegraseNF-kappa BReceptors, CCRCD4+ T cellsChemokine signallingHIV latencyIntegrationNF-κB

Identifiers

PMID27459960
PMCPMC4962537
OpenAlexW2503566884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.